330P A real-world multi-center prospective observational study of atezolizumab (Atezo) + bevacizumab (Bev) + carboplatin (CBDCA) + paclitaxel (PTX) (ABCP) in patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC after EGFR-TKIs failure

Authors :: S. Kuyama
H. Yoshioka
H. Kaneda
Y. Kataoka
S. Miura
N. Katakami
Y. Yamanaka
A. Tamiya
T. Yamada
T. Yokoyama
S. Hara
H. Tanaka
Y. Fujisaka
A. Nakamura
K. Azuma
M. Namba
A. Hata
K. Sawa
H. Ishikawa
T. Kurata
Source :: Annals of Oncology. 33:S1572
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Tools